Dr. Dino PratoEnvita Medical Centers · Founder and CEO at Envita Medical Centers

Cancer isn’t one-size-fits-all

31 Oct 2025 · 1 min

Watch on YouTube

0:31

In this brief monologue, the speaker denounces the conventional oncology paradigm as a one-size-fits-all approach that relies on double‑blind placebo clinical trials and NCCN guideline‑driven protocols. He argues that treating patients with the same cancer type and stage identically ignores the underlying biological heterogeneity revealed by deeper data analysis. The speaker asserts that each cancer is unique, and the current mass‑treatment model therefore misses the opportunity for truly individualized therapy.

Chapters

Conventional oncology. It's a one size fits all model. It's based on the double blind placebo clinical trials. That means that people with the same type and stage of cancer are all treated the same. So we can take a breast cancer, same type and stage, colon, same type, prostate, pancreatic, whatever, and they're given the same treatment based on the National Comprehensive Cancer Network guidelines. The problem is this is designed for the masses, but when you actually run more data, they're all unique. Each cancer is unique. And this is where they missed a boat.